News
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback